Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer
Top Cited Papers
Open Access
- 11 November 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (22), 6973-6979
- https://doi.org/10.1158/1078-0432.ccr-09-1525
Abstract
Purpose: The average weight-losing pancreatic cancer patient undergoing palliative therapy is frequently overweight rather than underweight, and this can confound conventional measures used for risk stratification. The aim of this study was to evaluate if weight and body composition, specifically sarcopenia, assessed from diagnostic computed tomography (CT) scans, is of prognostic value in patients with pancreatic cancer. The nature and extent of tissue loss over subsequent months was also evaluated. Experimental Design: A total of 111 patients entering a palliative therapy program, who had CT images and had undergone nutritional screening, were studied. In patients for whom follow-up scans were available (n = 44), longitudinal changes in body composition were studied at a mean of 230 ± 62 and 95 ± 60 days prior to demise. Results: Sixty-two patients (55.9%) were sarcopenic, 44 (39.6%) were overweight/obese, and 18 (16.2%) were both. Age ≥59 years (hazard ratio, 1.71; 95% confidence interval, 1.10-2.66; P = 0.018), and overweight/obese sarcopenia (hazard ratio, 2.07; 95% confidence interval, 1.23-3.50; P = 0.006) were identified as independent predictors of survival on multivariate analysis. Longitudinal analysis revealed that total fat-free mass index decreased from 15.5 ± 2.5 kg/m2 to 14.5 ± 2.0 kg/m2 (P = 0.002), and total fat mass index decreased from 7.5 ± 2.0kg/m2 to 6.0 ± 1.5kg/m2 (P < 0.0001) over 135 days. Conclusions: Sarcopenia in overweight/obese patients with advanced pancreatic cancer is an occult condition but can be identified using CT scans. This condition is an independent adverse prognostic indicator that should be considered for stratification of patients' entering clinical trials, systemic therapy, or support care programs. (Clin Cancer Res 2009;15(22):6973–9)Keywords
This publication has 37 references indexed in Scilit:
- Cancer cachexia is associated with the IL10 −1082 gene promoter polymorphism in patients with gastroesophageal malignancyThe American Journal of Clinical Nutrition, 2009
- Cachexia, survival and the acute phase responseCurrent Opinion in Supportive & Palliative Care, 2008
- Molecular Markers of Early Pancreatic CancerJournal of Clinical Oncology, 2005
- Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—Correlations with food intake, metabolism, exercise capacity, and hormonesCancer, 2005
- Inhibitor κB kinase is involved in the paracrine crosstalk between human fat and muscle cellsInternational Journal of Obesity, 2004
- Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancerClinical Nutrition, 2004
- Evaluating body composition of Italian prostate cancer patients without metastasesActa Diabetologica, 2003
- Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in EuropeEuropean Journal of Cancer, 1998
- THE VALIDITY OF SELF-REPORTS OF PAST BODY WEIGHTS BY U.S. ADULTSEpidemiology, 1995
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsAmerican Journal Of Medicine, 1980